Holen Sie sich die Stockscreener-App
139.94
1.19%
-1.68
Handel nachbörslich:
139.94
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$141.62
Offen:
$141.78
24-Stunden-Volumen:
1.52M
Relative Volume:
1.07
Marktkapitalisierung:
$20.52B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.53B
KGV:
13.38
EPS:
10.46
Netto-Cashflow:
$1.85B
1W Leistung:
+5.50%
1M Leistung:
+5.85%
6M Leistung:
-1.90%
1J Leistung:
-31.72%
1-Tages-Spanne:
$137.14
$142.28
1-Wochen-Bereich:
$131.52
$145.27
52-Wochen-Spanne:
$110.03
$205.19
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
139.94 | 20.47B | 9.61B | 1.53B | 1.85B | 10.46 |
|
LLY
Lilly Eli Co
|
742.91 | 659.07B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.76 | 428.83B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
213.00 | 374.37B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
128.42 | 245.16B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.05 | 213.51B | 63.43B | 16.42B | 14.72B | 6.49 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen Inc. $BIIB Stake Raised by B. Metzler seel. Sohn & Co. AG - MarketBeat
Biogen Shares Rally 1.43% on Key Therapeutic Advances and Strategic Expansion as $320M Volume Ranks 320th - AInvest
Biogen Showcases Lupus Pipeline But Investors Will Have To Wait For Data - insights.citeline.com
Western Digital, Adobe, Biogen See High Option Trading Volume - AInvest
Risk vs reward if holding onto Biogen Inc.2025 Analyst Calls & Reliable Trade Execution Plans - Newser
Stock Analysis | Biogen OutlookWeak Technicals Cloud Optimistic Fundamentals - AInvest
Investors Holding Back On Biogen Inc. (NASDAQ:BIIB) - 富途牛牛
Is it too late to sell Biogen Inc.Portfolio Gains Report & Daily Technical Forecast Reports - Newser
Biogen Thematic Pipeline Seminar: Lupus - MarketScreener
Should New Zorevunersen and LEQEMBI Launches Influence Biogen's (BIIB) Rare Disease Growth Strategy? - simplywall.st
Biogen Highlights Multiple Assets and Indications in Lupus - Biogen
Eisai and Biogen to launch new Alzheimer's treatment in the US - medwatch.com
Biogen, Eisai begin rolling FDA submissions for Leqembi injectable for starting dose - Seeking Alpha
These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and More - MSN
CW Advisors LLC Buys New Holdings in Biogen Inc. $BIIB - MarketBeat
Caisse DE Depot ET Placement DU Quebec Makes New Investment in Biogen Inc. $BIIB - MarketBeat
Ieq Capital LLC Grows Stock Position in Biogen Inc. $BIIB - MarketBeat
Is Biogen Inc. showing insider buying2025 Key Lessons & Smart Money Movement Alerts - khodrobank.com
Biogen Inc. $BIIB Stock Position Decreased by Canada Pension Plan Investment Board - MarketBeat
Can Biogen Inc. reach all time highs this year2025 Support & Resistance & Consistent Profit Trading Strategies - khodrobank.com
Will Biogen Inc. see short term momentumWeekly Volume Report & Free Reliable Trade Execution Plans - Newser
Biogen Inc. $BIIB Holdings Raised by Trexquant Investment LP - MarketBeat
Landscape Capital Management L.L.C. Takes $329,000 Position in Biogen Inc. $BIIB - MarketBeat
American Century Companies Inc. Cuts Stock Position in Biogen Inc. $BIIB - MarketBeat
BNP Paribas Financial Markets Has $50.11 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
The Game-Changing Potential of LEQEMBI® IQLIK™ in Early Alzheimer's Disease Treatment and Its Impact on Biogen and Eisai’s Market Position - AInvest
Visual analytics tools that track Biogen Inc. performanceJuly 2025 Final Week & Verified Technical Signals - Newser
Biogen Participating in the Cantor Global Healthcare Conference - Biogen
Real time breakdown of Biogen Inc. stock performance2025 Big Picture & Technical Buy Zone Confirmation - Newser
Evaluating Biogen Inc. with trendline analysisPrice Action & Reliable Volume Spike Trade Alerts - Newser
How institutional ownership impacts Biogen Inc. stockWeekly Earnings Recap & Low Risk High Win Rate Stock Picks - Newser
Biogen to Participate in Upcoming Healthcare Conferences - Biogen
Biogen Executive Makes a Significant Stock Sale - TipRanks
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - Quantisnow
Biogen's Stock Surges 5.60% on Bullish Candlestick Pattern and Elevated Volume Amid Overbought Technical Indicators - AInvest
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status - Placera.se
Eisai, Biogen begin FDA submission for Alzheimer’s autoinjector - Investing.com
First At-Home Injection Option for Alzheimer's: Eisai's LEQEMBI IQLIK Could Transform Treatment Access - Stock Titan
Biogen Jumps 5.6% on Heavy Volume as Technicals Signal Bullish Reversal - AInvest
Can Biogen Inc. sustain its profitabilityWeekly Stock Recap & Growth Oriented Trade Recommendations - خودرو بانک
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen’s Surging Stock: Is a Breakthrough Imminent? - StocksToTrade
Is Biogen Inc. stock undervalued right nowAnalyst Downgrade & Weekly Market Pulse Alerts - خودرو بانک
Biogen (BIIB) Stock Is Up, What You Need To Know - Yahoo Finance
Biogen’s Sudden Surge: A Strategic Insight? - timothysykes.com
Biogen’s Strategic Moves: New Horizons or Risk? - StocksToTrade
Biogen Inc. (BIIB)’s Alzheimer’s Drug Leqembi Wins EU Nod, Now Approved in 48 Countries - MSN
Sector Update: Health Care Stocks Retreat Tuesday Afternoon - MarketScreener
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biogen Inc-Aktie (BIIB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Singhal Priya | Head of Development |
Sep 02 '25 |
Sale |
133.55 |
517 |
69,045 |
5,772 |
9.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):